Antibodies to M-CSF
    53.
    发明授权
    Antibodies to M-CSF 有权
    M-CSF抗体

    公开(公告)号:US07592430B2

    公开(公告)日:2009-09-22

    申请号:US10938353

    申请日:2004-09-09

    IPC分类号: C07K16/00

    摘要: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies. The invention also relates to transgenic animals and transgenic plants comprising nucleic acid molecules of the present invention.

    摘要翻译: 本发明涉及特异性结合M-CSF,优选人M-CSF的抗体及其抗原结合部分,其功能是抑制M-CSF。 本发明还涉及人抗M-CSF抗体及其抗原结合部分。 本发明还涉及嵌合,双特异性,衍生的单链抗体或融合蛋白的部分的抗体。 本发明还涉及衍生自人抗M-CSF抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及制备人抗M-CSF抗体的方法,包含这些抗体的组合物和使用该抗体和组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗M-CSF抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的转基因动物和转基因植物。

    HUMAN FGF RECEPTOR AND BETA-KLOTHO BINDING PROTEINS
    60.
    发明申请
    HUMAN FGF RECEPTOR AND BETA-KLOTHO BINDING PROTEINS 有权
    人FGF受体和BETA-KLOTHO结合蛋白

    公开(公告)号:US20130129725A1

    公开(公告)日:2013-05-23

    申请号:US13641041

    申请日:2011-04-13

    IPC分类号: A61K39/395 C07K16/40

    摘要: The present invention provides compositions and methods relating to or derived from antigen binding proteins and antigen binding protein-FGF21 fusions that specifically bind to β-Klotho, or β-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins and antigen binding protein-FGF21 fusions induce FGF21-like signaling. In some embodiments, an antigen binding protein or antigen binding protein-FGF21 fusion antigen binding component is a fully human, humanized, or chimeric antibody, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to β-Klotho, or β-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins and antigen binding protein-FGF21 fusions, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.

    摘要翻译: 本发明提供与抗原结合蛋白和特异性结合β-Klotho或β-Klotho以及FGFR1c,FGFR2c,FGFR3c和FGFR4中的一种或多种的抗原结合蛋白和抗原结合蛋白-FGF21融合物相关或衍生的组合物和方法。 在一些实施方案中,抗原结合蛋白和抗原结合蛋白FGF21融合物诱导FGF21样信号传导。 在一些实施方案中,抗原结合蛋白或抗原结合蛋白-FGF21融合抗原结合组分是完全人,人源化或嵌合抗体,这种抗体的结合片段和衍生物,以及特异性结合β-Klotho或β- Klotho和FGFR1c,FGFR2c,FGFR3c和FGFR4中的一种或多种。 其他实施方案提供编码这种抗原结合蛋白和抗原结合蛋白-FGF21融合体的核酸,及其片段和衍生物,以及多肽,包含这种多核苷酸的细胞,制备这种抗原结合蛋白的方法和抗原结合蛋白-FGF21融合物, 其衍生物和多肽,以及使用这种抗原结合蛋白和抗原结合蛋白-FGF21融合体,其片段和衍生物和多肽的方法,包括治疗或诊断患有2型糖尿病,肥胖症,NASH,代谢综合征和 相关疾病或病症。